ADVFN Logo
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Rain Oncology Inc

Rain Oncology Inc (RAIN)

1.21
0.00
(0.00%)
At close: August 01 4:00PM
1.21
0.00
( 0.00% )

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
1.21
Bid
1.27
Ask
1.21
Volume
-
0.00 Day's Range 0.00
0.82 52 Week Range 1.35
Previous Close
1.21
Open
-
Last Trade
Last Trade Time
-
Average Volume (3m)
-
Financial Volume
-
VWAP
-

RAIN Latest News

Share Repurchase Announcement Causes Premarket Buying Pressure

A California-based green tech firm just announced this morning that the company will implement a 90-day plan to buyback shares in addition to announcing the company will move the To read the full...

Global Warming Solutions and Vega Energy Execute Letter of Intent

Global Warming Solutions, Inc. (Pink Sheets:GWSO) ? a developer of technologies aimed at mitigating the effects of global warming ? today announced that the company has signed...

Global Warming Solutions, Inc., Appoints Its European Sales Manager

Global Warming Solutions, Inc. (Pink Sheets:GWSO) is pleased to announce the appointment of Mr. Antonino Adamo to its Board of Directors. Mr. Adamo becomes the European Sales...

Global Warming Solutions and Solar Wind Provide Update on Joint Testing

Global Warming Solutions, Inc. (Pink Sheets:GWSO) ? a developer of technologies aimed at mitigating the effects of global warming ? today provided an update on the progress of...

Global Warming Solutions Completes Audit and Prepares for OTCBB Listing

Global Warming Solutions, Inc. (Pink Sheets:GWSO) ? a developer of technologies aimed at mitigating the effects of global warming ? today announced that it has completed its...

Global Warming Solutions Releases Solar Energy Technologies Presentation

Global Warming Solutions, Inc. (Pink Sheets:GWSO) ? a developer of technologies aimed at mitigating the effects of global warming ? today released a twenty-four page...

Global Warming Solutions Initiates R & D for 1 MW LETG Solar Power Plant

Global Warming Solutions, Inc. (Pink Sheets:GWSO) ? a developer of technologies aimed at mitigating the effects of global warming ? today announced that the company initiated...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000CS
40000000CS
120000000CS
260000000CS
52-0.09-6.923076923081.31.350.822434471.11826117CS
156-15.45-92.737094837916.6618.77950.822975833.33152299CS
260-20.89-94.524886877822.123.90.822900384.39374252CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
VCNXVaccinex Inc
$ 6.70
(38.57%)
188.47k
XCURExicure Inc
$ 0.68
(36.46%)
351.88k
TNDMTandem Diabetes Care Inc
$ 45.0005
(27.92%)
55.9k
DASHDoorDash Inc
$ 123.50
(14.06%)
606.63k
TURBTurbo Energy SA
$ 1.4599
(12.30%)
25.85k
VWEVintage Wine Estates Inc
$ 0.0227
(-18.05%)
854.32k
TEAMAtlassian Corporation PLC
$ 146.95
(-15.20%)
70.18k
INTCIntel Corporation
$ 25.99
(-10.72%)
5.85M
OCTOEightco Holdings Inc
$ 0.30
(-9.53%)
39.37k
AMZZGraniteShares 2X Long AMZN Daily ETF
$ 23.91
(-8.98%)
28.62k
INTCIntel Corporation
$ 25.99
(-10.72%)
5.85M
AMZNAmazon.com Inc
$ 176.50
(-4.08%)
4.78M
BNDVanguard Total Bond Market
$ 73.57
(0.00%)
3.2M
NVDANVIDIA Corporation
$ 110.0503
(0.66%)
3.16M
SQQQProShares UltraPro Short QQQ
$ 9.35
(1.41%)
2.46M

RAIN Discussion

View Posts
Milesblue42 Milesblue42 7 months ago
BRODSKY & SMITH SHAREHOLDER UPDATE:




BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Alteryx, Inc. (NYSE -- AYX), Rain Oncology, Inc. (Nasdaq -- RAIN), Consolidated Communications Holdings, Inc. (Nasdaq - CNSL), Cerevel Therapeutics Holdings, Inc. (Nasdaq -- CERE)

BALA CYNWYD, Pa., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky @bulldop01Toror-4847. There is no cost or financial obligation to you.

Alteryx, Inc. (NYSE -- AYX)

Under the terms of the agreement, Alteryx will be acquired by Clearlake Capital Group, L.P. ("Clearlake") and Insight Partners ("Insight," and together with Clearlake, the "Buyers"). Alteryx stockholders will receive $48.25 per share in cash for each share of Alteryx Class A or Class B common stock that they own. The investigation concerns whether the Alteryx Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether Buyers are paying fair value to shareholders of the Company.

https://www.marketwatch.com/press-release/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-alteryx-inc-nyse-ayx-rain-oncology-inc-nasdaq-rain-consolidated-communications-holdings-inc-nasdaq-cnsl-cerevel-therapeutics-holdings-inc-nasdaq-cere-c0309f5f?mod=mw_quote_news_seemore

https://www.brodskysmith.com/cases/alteryx-inc-nyse-ayx/.
πŸ‘οΈ0
axelvento axelvento 8 months ago
it will still be on the market?
this is the question
πŸ‘οΈ0
PennyWorld PennyWorld 8 months ago
Not sure I understand your point. $1.16 is $1.16. Good for some SH.

For me, now I have to swing trade this at a higher range. Buy at 1.10, take profits at s 1.16
πŸ‘οΈ0
axelvento axelvento 8 months ago
so what? Pathos has established a separate, wholly-owned subsidiary to complete the Transaction. Following the tender offer closing, this subsidiary will be merged into Rain with Rain as the surviving entity of the merger, which will then operate as a separate, wholly-owned subsidiary of Pathos. If the tender offer is successful, the Transaction is expected to close in January 2024.
πŸ‘οΈ0
Milesblue42 Milesblue42 8 months ago
NEW PR RAIN being bought out

https://www.marketwatch.com/press-release/rain-oncology-enters-into-agreement-to-be-acquired-by-pathos-ai-for-1-16-in-cash-per-share-plus-contingent-value-rights-06ce1004?mod=mw_quote_news_seemore

Press Release
Rain Oncology Enters into Agreement to be Acquired by Pathos AI for $1.16 in Cash per Share Plus Contingent Value Rights
πŸ‘οΈ0
Milesblue42 Milesblue42 8 months ago
Was there a Trading Halt? Or Rumor??
πŸ‘οΈ0
PennyWorld PennyWorld 8 months ago
I don't think so. I suspect we'll see another pull back. Profit taking.
πŸ‘οΈ0
Milesblue42 Milesblue42 8 months ago
Are We getting......Close??
πŸ‘οΈ0
Monksdream Monksdream 11 months ago
RAIN new 52 week low
πŸ‘οΈ0
Jeritron5100 Jeritron5100 1 year ago
Range is tightening. Big move coming soon
πŸ‘οΈ0
Jeritron5100 Jeritron5100 1 year ago
Held 1.23 strong today then a nice late run to 1.30. I like where this is headed. If this first breaks 1.33 and then ultimately 1.37 next leg up will be huge.
πŸ‘οΈ0
axelvento axelvento 1 year ago
$RAIN 3.42 in cash per share = MULTIBAGGER$
👍️ 1
axelvento axelvento 1 year ago
just waiting for news from Tang. Price will stay in this channel until he is done loading or news breaks on a take over bid.
πŸ‘οΈ0
axelvento axelvento 1 year ago
I don’t see why this man would invest millions & not do nothing. He did a takeover bid in JNCE 3 months ago with fire results for shareholders. Expecting a pop here very soon
👍️ 1
axelvento axelvento 1 year ago
last arrived-great signal: https://fintel.io/so/us/rain/tang-capital-partners-lp

deep hands.
πŸ‘οΈ0
Sauerkraut Sauerkraut 1 year ago
Bad P3 Trial anouncmet. But not that bad, still better than everything else in that sector of care.....imo
πŸ‘οΈ0
PennyWorld PennyWorld 1 year ago
Reason for PPS crash... failure to meet FDA Phase 3 primary endpoint for MANTRA.
https://finance.yahoo.com/news/rain-oncology-announces-topline-results-120000095.html?.tsrc=rss

However, RAIN does have two other drugs in the pipeline, but unfortunately neither one are in Phase 3 trials.
Pipeline....
https://www.rainoncology.com/pipeline

Fundamentals (debt to equity, O/S, etc) are great, and I see no historical record of an R/S.

IMO RAIN is oversold, but the panic selling may not be complete. It should see a gradual (slow) recovery to the upside over time. But without positive news on the FDA front, I see these price levels as setting a new support level for quite some time.

JMHO
πŸ‘οΈ0
WARHAMMER WARHAMMER 1 year ago
Knife fell, time to look forward.
πŸ‘οΈ0
PennyWorld PennyWorld 1 year ago
Why? Could be a falling knife.
πŸ‘οΈ0
WARHAMMER WARHAMMER 1 year ago
Who cares. :)
πŸ‘οΈ0
PennyWorld PennyWorld 1 year ago
What caused the price to crash in May?
πŸ‘οΈ0
WARHAMMER WARHAMMER 1 year ago
RAIN - being accumulated-- when "they" are done-- its gonna fly hard
πŸ‘οΈ0
axelvento axelvento 1 year ago
Tang bought 30% of the float...
πŸ‘οΈ0
Sauerkraut Sauerkraut 1 year ago
Let's go
πŸ‘οΈ0
Sauerkraut Sauerkraut 1 year ago
Fore sure, I agree. But I'm not here to protect retail......imo
πŸ‘οΈ0
TheFinalCD TheFinalCD 1 year ago
TRADING HALF THE FLOAT AND NOT MUCH MOVEMENT IS CRIMINAL


LOL
πŸ‘οΈ0
Sauerkraut Sauerkraut 1 year ago
Let's go. $2.5+
πŸ‘οΈ0
axelvento axelvento 1 year ago
Planned MANTRA-2 clinical update at a medical conference in 4Q 2023

PHASE 2- it works very well

Milademetan Shows Early Activity in MDM2-Amplified Advanced Solid Tumors

Notably, activity with the MDM2 inhibitor was observed in patients with heavily pretreated, refractory disease.
πŸ‘οΈ0
axelvento axelvento 1 year ago
more news to come:

Evaluate avenues to enhance the pipeline through precision oncology program acquisition-
πŸ‘οΈ0
axelvento axelvento 1 year ago
$RAIN 36.4 million shares of common stock outstanding
Year-end 2023 cash guidance of $75-$80 million, and cash runway to year-end 2026
πŸ‘οΈ0
axelvento axelvento 1 year ago
There's one piece left-- Rain Therapeutics Provides Interim Analysis of Phase 2 Basket Trial of Milademetan for MDM2-Amplified Advanced Solid Tumors (MANTRA-2)

- Two patients exhibited an unconfirmed partial response at their first scan, and two additional patients saw promising tumor regression activity out of ten efficacy evaluable patients, demonstrating monotherapy activity of milademetan in MDM2-amplified patients -

At the data cutoff of October 26, 2022, 17 patients were enrolled. Two unconfirmed partial responses were observed in patients with pancreatic and lung cancer with a tumor regression of 34% and 30% with lung cancer, respectively. Additionally, there was promising tumor regression of 29% in a patient with biliary tract cancer and 27% in a patient with breast cancer; both are receiving continued investigational therapy.

https://www.rainoncology.com/news-press-releases/rain-therapeutics-provides-interim-analysis-of-phase-2-basket-trial-of-milademetan-for-mdm2-amplified-advanced-solid-tumors-mantra-2
πŸ‘οΈ0
axelvento axelvento 1 year ago
NEW$$$$-Tang Capital Partners Lp ownership in RAIN / Rain Oncology Inc
2023-06-01 - Tang Capital Partners Lp has filed an SC 13D form with the Securities and Exchange Commission (SEC) disclosing ownership of 3,740,341 shares of Rain Oncology Inc (US:RAIN). This represents 14.1 percent ownership of the company.

https://fintel.io/so/us/rain/tang-capital-partners-lp
πŸ‘οΈ0
TheFinalCD TheFinalCD 1 year ago
also bottom play, stock was $8 with a low float

so watch it
πŸ‘οΈ0
pitacorp pitacorp 1 year ago
it goes up AH because if that SEC report of ownership??
πŸ‘οΈ0
TheFinalCD TheFinalCD 1 year ago
make it RAIN https://www.sec.gov/Archives/edgar/data/1178579/000120919123033446/xslF345X04/doc4.xml
πŸ‘οΈ0
nate2028 nate2028 1 year ago
$2 Price targets but can’t even hold $1
πŸ‘οΈ0
nate2028 nate2028 1 year ago
Yikes this is in bad shape
πŸ‘οΈ0
Stock_Gambit Stock_Gambit 1 year ago
Yeah. The targets are still much higher than $1….. should see incremental moves soon
πŸ‘οΈ0
bigbux1 bigbux1 1 year ago
Thanks, looks like a good entry
πŸ‘οΈ0
Stock_Gambit Stock_Gambit 1 year ago
Didn’t meet their phase 3 goals. But they still have a $16 target.
πŸ‘οΈ0
bigbux1 bigbux1 1 year ago
Why the big sell off? Don't see any news...
πŸ‘οΈ0
surf1944 surf1944 1 year ago
https://stockcharts.com/h-sc/ui?s=RAIN&p=D&yr=0&mn=6&dy=0&id=p38090673899

https://www.barchart.com/stocks/quotes/RAIN/technical-chart?plot=CANDLE&volume=total&data=DO&density=ML&pricesOn=1&asPctChange=0&logscale=0&indicators=ACCUM;SMA(20);SMA(50);SMA(100);SMA(200);CHKMF(20)&sym=SYSX&grid=1&height=210&studyheight=100

https://www.barchart.com/stocks/quotes/RAIN/opinion

https://finance.yahoo.com/quote/RAIN?p=RAIN

This is why you sell biotech rally's prior to the news release.
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock